The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
BUSINESS Rohto Bags Majority Stake in Austria Pharma to Boost European Biz
June 10, 2024
-
ORGANIZATION EFPIA Japan Issues New Proposal on HTA, Calls for Transparency
June 10, 2024
-
REGULATORY LDP Policy Board Endorses Fiscal Consolidation HQ’s Proposal to Extend CEAs
June 10, 2024
-
BUSINESS Towa Files NDA for Rivastigmine Twice Weekly Transdermal Patch in Japan
June 10, 2024
-
BUSINESS Novavax COVID Vaccine to Be Adapted to JN.1 Strain: Takeda
June 10, 2024
-
BUSINESS Shionogi Gets Option Rights to Cilcare’s Hearing Loss Assets
June 10, 2024
-
REGULATORY Japan Grants Orphan Tag to Cannabidiol, 6 More APIs
June 10, 2024
-
COMMENTARY With Only 5 Months Until Nitrosamine Self-Inspection Deadline, Many Challenges Remain
June 7, 2024
-
REGULATORY Health-Savvy Lawmakers Urge Revamp of Off-Year Revisions: LDP Policy Panel
June 7, 2024
-
REGULATORY Abolish Off-Year Revisions, No to Broader CEA Use: Eto Group to Ministers
June 7, 2024
-
REGULATORY LDP League on Medical Patches Urges Clarification of “Medical Necessity” as New Coverage Rule Looms
June 7, 2024
-
BUSINESS Maruho Licenses Amenalief Rights in 10 ASEAN States to Singapore Firm
June 7, 2024
-
BUSINESS Overseas Sales Ratio of 25 Japan Drug Makers Reaches 67% in FY2023: Tally
June 6, 2024
-
REGULATORY Japan Eases Rule on Regulatory Submissions for Combination Therapies
June 6, 2024
-
BUSINESS TAK-861 Hits Main Goal in PIIb Trial, PIII Set to Begin in 1H FY2024: Takeda
June 6, 2024
-
BUSINESS Shionogi to Open Antimicrobial R&D Center in San Diego
June 6, 2024
-
BUSINESS Enhertu Scores in Earlier Line for HER2-Low Breast Cancer, Shows Promise in Ultralow Cases
June 6, 2024
-
BUSINESS PeptiDream Doses 1st Patient with CA9-Targeted Radiopeptide
June 6, 2024
-
BUSINESS Japan Vaccine Market Projected to Top 280 Billion Yen in FY2024: Fuji Keizai
June 6, 2024
-
ORGANIZATION 135 Meds Still in Lag/Loss State in Japan, JPMA Task Force Revving Up Fight
June 5, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…